ProMIS Neurosciences announced that preclinical data supporting the potential role of its lead product candidate, PMN310, as a treatment for AD will be highlighted in an oral presentation at the 4th International Conference on Cognitive & Behavioral Neurosciences, ICBN, taking place from September 12-13, 2024 in Lisbon, Portugal. In the studies, the binding of PMN310 and other Ass-directed antibodies to a toxic oligomer-enriched low molecular fraction of brain extract from AD patients was evaluated by surface plasmon resonance, with and without monomer competition. The results indicated that PMN310 showed little or no interaction with monomers and was among the least impacted by excess monomer competition in binding to toxic oligomers in AD brain extract.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMN:
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- ProMIS Neurosciences files to sell 56.51M common shares for holders
- ProMIS Neurosciences reports Q2 EPS (13c) vs (27c) last year
- ProMIS Neurosciences annouces data on pathogenic role of misfolded SOD1
Questions or Comments about the article? Write to editor@tipranks.com